A carregar...
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
Ibrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of patients with relapsed refractory chronic lymphocytic leukemia (RR-CLL). We describe the characteristics, causes of discontinuation, and outcomes in patients who discontinued treatment with ibrutinib. One hundred twenty-se...
Na minha lista:
| Publicado no: | Blood |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4467871/ https://ncbi.nlm.nih.gov/pubmed/25573991 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-09-603670 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|